Clinical Role - Payer
Pharmacy Times® is a leader in providing the latest clinical updates, patient counseling tools and innovative solutions to payers, pharmacy benefit managers, formulary chairs and directors, managed care directors, quality assurance directors, and Medicaid/Medicare directors.
Counties in Medicaid expansion states saw an 11% lower rate of heroin deaths and a 10% lower rate of deaths involving synthetic opioids compared with counties in non-expansion states.
Lower-priced versions of Humalog Mix75/25 KwikPen and Humalog Junior KwikPen will be available in mid-April and will have 50% lower list prices compared with branded versions.
The proposal, which is still largely conceptual, was a part of Newsom’s proposed 2020-2021 budget.1
There are some basic tips or tricks to getting the most out of your insurance plan and to maintain the care patients are accustomed to.
Manufacturers have selected AllianceRx Walgreens as their limited distribution drug partner for drugs that treat conditions such as myelofibrosis, cystic fibrosis, and non-metastatic castration-resistant prostate cancer.
Girish Dighe, PharmD, MS, explains why it's important to understand more than just the revenue integrity piece of the puzzle.
A study found that intravenous immune globulin dosing optimization through alternative dosing weights represents a significant source of waste reduction and cost reduction.
Top news of the day from across the health care landscape.
Adoption of digital and focus on value set to transform current prior authorization processes.
A recent study published in CANCER indicates that for patients with both HIV and cancer, implementation of the Patient Protection and Affordable Care Act (ACA) improved insurance coverage, both in states that expanded Medicaid coverage and in states that did not.1
Informed by the newly released NCPA 2019 Digest, members of community pharmacy organizations elaborate on the ongoing discussion of value-based care and reimbursement for community pharmacists.
Texas oncologist Stephen Hahn, MD, is expected to receive the Trump administration’s nomination for the role of FDA Commissioner, a move that had been anticipated by federal insiders.